MedTrace Logo

The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC)

NCT03472716 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2022-12-06

No results posted yet for this study

Summary

The primary objective of this trial is to evaluate the correlation between the intensity of the protein big-h3 expression at tumoural microenvironment and the TNM/UICC staging (from I to IV) of pancreatic adenocarcinoma lesion.

Conditions

  • Pancreas Adenocarcinoma

Interventions

PROCEDURE

Biological Samples

5 ml blood sample and one tumoural sample (either a fresh biopsy or the initial diagnosis biopsy). In case of relapse, new samples will be performed (blood and tumoral samples)

Sponsors & Collaborators

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • DE LA FOUCHARDIERE Christelle, Dr · Centre Leon Berard

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-22
Primary Completion
2023-05-31
Completion
2023-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03472716 on ClinicalTrials.gov